New drug combo shows promise for Hard-to-Treat cancers
Disease control
Ongoing
This early-phase study tests an experimental drug called MOMA-313, given alone or with another drug (olaparib), in people with advanced solid tumors that have a specific DNA repair problem (HR deficiency). The goal is to find a safe dose and see if the drug shrinks tumors. About …
Phase: PHASE1 • Sponsor: MOMA Therapeutics • Aim: Disease control
Last updated Jun 15, 2026 19:02 UTC